SWK Holdings Corporation — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Amounts are in U.S. dollars; financial statement figures are in thousands unless stated otherwise.
Business context
SWK is a specialty finance and asset management company focused on life sciences, with Finance Receivables and Pharmaceutical Development segments. Its portfolio includes term loans and royalty interests; its Enteris subsidiary provides pharmaceutical development, manufacturing and licensing services.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Total revenue | $11.779 million | $9.411 million |
| Operating income | $1.472 million | $5.322 million |
| Net income | $0.861 million | $4.635 million |
| Diluted earnings per share | $0.07 | $0.36 |
| Operating cash flow | $4.430 million | $0.664 million |
| Cash and cash equivalents | $5.498 million | $4.503 million at Dec. 31, 2023 |
| Net finance receivables | $261.285 million | $274.504 million at Dec. 31, 2023 |
Revenue rose about 25%, primarily as interest and fees increased on new and existing loans. Net income fell about 81%; the period included a $5.323 million credit-loss provision, including a $6.0 million impairment on the Trio loan. Interest expense increased to $1.256 million from $0.182 million, mainly reflecting the 9% senior notes issued in 2023. The filing reports no separate formal margin guidance.
Cash from investing was $9.181 million, versus $11.082 million used in Q1 2023, principally reflecting finance-receivable repayments. Financing used $13.349 million, including repayment of $12.350 million on the revolving facility and $0.999 million of share repurchases. Current assets were $13.936 million and current liabilities $4.376 million at quarter-end.
Debt, portfolio risk and material developments
- There were no borrowings under the revolving credit facility at March 31, 2024; $55 million was available. The facility has $60 million in commitments, subject to its terms. SWK reported compliance with all facility covenants.
- The 9% senior notes have $32.969 million principal outstanding and mature January 31, 2027. Net carrying value was $30.927 million.
- Five receivables were on nonaccrual, with a combined net carrying value of $25.364 million. Trio was impaired by $6.0 million; the company also identified Exeevo, Flowonix, Best ABT and Ideal Implant as nonaccrual positions.
- The allowance for credit losses was $13.224 million, down from $13.901 million at year-end after the quarter’s provision and $6.0 million in write-offs. Management cautions that the estimate could change, potentially materially.
- SWK entered an exclusive option and asset purchase agreement with AptarGroup relating to certain Enteris CDMO assets. The option must be exercised by January 1, 2026. The first low-single-digit-million option fee was paid in April 2024; guaranteed revenue payments are contemplated for 2024 and 2025. No guaranteed revenue was recognized in Q1, and the revenue-recognition policy is still being evaluated.
Outlook, risks and contingencies
Management expects the existing finance-receivables assets to generate positive cash flows in 2024, but says timing of new investments and repayments is difficult to predict and gives no assurance of results. The company does not assume near-term borrower repayments. Key risks include concentration in life sciences, borrower credit deterioration, uncertainty in credit-loss estimates, interest-rate changes and inflation affecting portfolio companies. SWK does not currently hedge interest-rate exposure. Unfunded commitments were $5 million, contingent on contractual conditions. The company reported no legal proceeding expected to have a material effect and no material change to previously disclosed risk factors.
Disclosure controls were assessed as effective, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Progress and recoverability of the five nonaccrual positions, especially the Trio impairment and the Flowonix royalty.
- Future credit-loss provisions, write-offs and portfolio performance, including the basis for the allowance estimate.
- Terms, payment timing and revenue recognition for AptarGroup’s option fee and guaranteed revenue arrangements.
- Cash generation and repayment trends in the receivables portfolio, alongside the $55 million of reported revolver availability and covenant compliance.
- Debt servicing costs and refinancing or redemption considerations for the 9% notes due in 2027.